Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annu...(be ofsignificant interest to potential p...),Health

Poster presentation details are as follows:

-- First-Line Treatment of Hormone Refractory Prostate Cancer: Abstract

#5153

A Phase 2 study of picoplatin with docetaxel and prednisone in

chemotherapy-naive patients with metastatic hormone-refractory

prostate cancer (HRPC)

Roman L, Karlov P, Cheporov S, Lopatkin N, Breitz H, Karlin D, Baker G.

General Poster Session: Saturday, May 31, from 8 a.m. to 12 p.m. CDT

S Hall A1, Poster #16A

-- First-line Treatment of Colorectal Cancer: Abstract #4100

First-line Phase 1b and 2 studies of picoplatin in combination with

5-fluorouracil and leucovorin, FOLPI, as a potential

neuropathy-sparing therapy for colorectal cancer

Cheporov S, Gladkov O, Biakhov M, Breitz H, Karlin D, Baker G.

General Poster Session: Monday, June 2, from 8 a.m. to 12 p.m. CDT

S Hall A1, Poster #14B

In addition, Don S. Dizon, M.D., assistant professor of obstetrics-gynecology and medicine at the Warren Alpert Medical School of Brown University, will present data from a Phase 1 trial of picoplatin in patients with ovarian cancer:

-- Phase 1 Combination Study with Pegylated Liposomal Doxorubicin

(including Ovarian Cancer): Abstract #2568,

Final results of a Phase 1 study of picoplatin and pegylated liposomal

doxorubicin in advanced solid tumor malignancies

Dizon DS, Maluf F, Aghajanian CA, Daud A, Sabbatini P, Soignet S,

Pezzulli S and Spriggs DR.

General Poster Session: Sunday, June 1, from 2 p.m. to 6:00 p.m. CDT

S Hall A1, Poster #12H

Poniard Investor Event

In addition to the picoplatin
'/>"/>